Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. (BTMD) operates in the specialized field of hormone optimization, offering growth practice-building solutions. The company's primary focus is to empower Biote-certified practitioners with the tools and knowledge required to establish, build, and effectively implement hormone optimization programs. These programs are designed to provide personalized solutions tailored to individual patient needs.
Biote Corp. provides a comprehensive suite of components to its practitioners, including training, marketing support, and ongoing education. This holistic approach ensures that practitioners are well-equipped to deliver high-quality care in the hormone optimization space. The company's commitment to education and support is a key differentiator, enabling practitioners to stay at the forefront of this rapidly evolving field.
Recent achievements by Biote Corp. include expanding its network of certified practitioners and forging new partnerships aimed at enhancing its service offerings. The company continues to invest in research and development to improve its products and services, ensuring that they meet the highest standards of efficacy and safety.
Financially, Biote Corp. has demonstrated steady growth, driven by the increasing demand for hormone optimization solutions. The company's strategic initiatives and robust business model have positioned it well to capitalize on emerging opportunities in the healthcare sector.
For those interested in the latest updates and developments from Biote Corp., the company regularly releases news and updates, which are accessible through various channels.
Biote Corp. (Nasdaq: BTMD) has partnered with IMAC Holdings (Nasdaq: BACK) to introduce Biote's hormone optimization services in IMAC's outpatient clinics. This collaboration aims to enhance patient care by integrating innovative treatments for obesity and chronic pain. Training for IMAC professionals on the Biote Method is set to begin in September. Biote specializes in building medical practices focused on hormone optimization, while IMAC provides regenerative rehabilitation for musculoskeletal and neurological conditions.
Biote Corp. has received approval from The Nasdaq Stock Market to relist its common stock and warrants. Trading will resume under the ticker symbols BTMD for common stock and BTMDW for warrants starting on August 29, 2022. CEO Terry Weber expressed gratitude for Nasdaq's support in confirming the company meets the initial listing criteria. Biote operates within the hormone optimization sector, providing practitioners with the necessary tools to establish and run hormone therapy centers.
Biote Corp, a leader in hormone optimization, has appointed Samar Kamdar as Chief Financial Officer. Kamdar, with extensive financial leadership experience across various industries, will oversee financial operations to enhance revenue growth and profitability. Previously, he held CFO roles at Slync.io and TaxAct and worked with companies like PepsiCo. CEO Terry Weber expressed confidence in Kamdar's ability to drive capital allocation strategies and optimize growth. Biote focuses on enhancing medical practices related to hormone therapy.
Biote (OTC-PINK:BTMD) issued a correction regarding its operating loss and net income for the three and six months ended June 30, 2022. The corrected figures show a larger operating loss and lower net income than previously reported. Specifically, the loss from operations for Q2 2022 increased to $85,603,000 from $76,186,000, and net income decreased to $40,341,000 from $49,710,000. The corrections stemmed from previously omitted transaction-related expenses, primarily linked to a $7.2 million charge related to a business combination with Haymaker Acquisition Corp. III.
Biote reported strong Q2 2022 financial results, with revenue of $41.4 million, a 19% increase year-over-year, and net income of $49.7 million, a 409% year-over-year rise, primarily due to transaction-related items. Adjusted EBITDA grew 21% to $13.1 million. The company maintains its 2022 revenue guidance of $160-166 million and raises adjusted EBITDA guidance to $47-51 million. Biote is expanding its sales force and exploring markets outside its core geography while focusing on clinical research to enhance its offerings.
biote Corp. (Nasdaq: BTMD) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call is scheduled for 8:30 a.m. ET on August 10, 2022, where CEO Terry Weber will discuss these results and provide a business update. Biote, a leader in hormone optimization, went public on May 27, 2022. The company offers a range of support to certified practitioners, enhancing hormone therapy through education and software solutions.
Biote Corp. (Nasdaq: BTMD) has appointed Dr. Ross W. McQuivey as Chief Medical Officer, effective June 10, 2022. Dr. McQuivey brings over 20 years of experience in medical leadership, having previously served as CMO at Laborie Medical Technologies. His role will focus on driving clinical research and expanding the Biote Method in mainstream medicine. CEO Terry Weber expressed confidence in Dr. McQuivey’s experience, highlighting its alignment with Biote’s strategic growth plans in the hormone optimization sector.
Biote Corp. (Nasdaq: BTMD) announces a presentation by CEO Terry Weber at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:30 p.m. ET, in New York City. The event will be webcasted live with a replay available for 90 days. In addition, Weber and Chairman Marc Beer will engage in investor meetings during the conference. Biote focuses on hormone optimization, training practitioners to detect and address hormone-related aging conditions. The company went public on Nasdaq on May 27, 2022.
Biote Corp., a medical practice-building company specializing in hormone optimization, has completed its business combination with Haymaker Acquisition Corp. III. This transaction, approved on May 24, 2022, allows Biote to enhance its growth and solidify its market position, with shares trading under the ticker BTMD starting May 27, 2022. The company aims to transform hormone optimization through a robust support network for practitioners and expects to report strong Q2 results in August.
FAQ
What is the current stock price of Biote (BTMD)?
What is the market cap of Biote (BTMD)?
What does Biote Corp. do?
Who are Biote-certified practitioners?
What kind of support does Biote Corp. provide to practitioners?
What recent achievements has Biote Corp. made?
How does Biote Corp. ensure the quality of its hormone optimization solutions?
What is Biote Corp.'s financial condition?
How can I stay updated on Biote Corp.'s latest news?
What are the core components provided by Biote Corp. to practitioners?
Why is hormone optimization important?
Who can benefit from Biote Corp.'s hormone optimization programs?
